Amalgamated Bank’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Amalgamated Bank’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-16,298	Closed	-$62K	–	1733
2020 Q1	$62K	Sell	16,298 -774	-5%	-$3.33K	﹤0.01%	1549
2019 Q4	$87K	Buy	17,072 +1,116	+7%	+$5.9K	﹤0.01%	1745
2019 Q3	$81K	Sell	15,956 -174	-1%	-$868	﹤0.01%	1671
2019 Q2	$100K	Buy	16,130 +3,187	+25%	+$15.4K	﹤0.01%	1690
2019 Q1	$60K	Buy	12,943 +360	+3%	+$1.63K	﹤0.01%	1634
2018 Q4	$53K	Buy	+12,583	New	+$64.1K	﹤0.01%	1562
2018 Q3	–	Sell	-12,047	Closed	-$97K	–	1701
2018 Q2	$97K	Buy	12,047 +1,875	+18%	+$14.3K	﹤0.01%	1659
2018 Q1	$76K	Sell	10,172 -250	-2%	-$1.66K	﹤0.01%	1547
2017 Q4	$62K	Buy	+10,422	New	+$63.3K	﹤0.01%	1597

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Amalgamated Bank's PGNX Position: Q2 2020 in Review

Amalgamated Bank sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 16,298 shares — an estimated $62K sold.

Amalgamated Bank first reported a position in PGNX in Q4 2017 and held it in 9 quarters. The position peaked at $100K in Q2 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Amalgamated Bank reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Amalgamated Bank sold 16,298 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $62K.
Amalgamated Bank first reported a position in Progenics Pharmaceuticals Inc in Q4 2017 and held it in 9 quarters.
Amalgamated Bank's Progenics Pharmaceuticals Inc position peaked at $100K in Q2 2019.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Amalgamated Bank's 13F filing for Q2 2020, filed 10 Aug 2020.